浩宇
浩宇生醫 Stock: price and insider trades · Taiwan
浩宇生醫: what insiders have been doing
浩宇生醫 has a thin disclosure history in our data (latest filing: 24 February 2025). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by TWSE / TPEx (MOPS). They describe what insiders did and are not a recommendation.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
as of FY 2025FY ended December 2025 · cache
NT$22
Analyst consensus
Income statement
RevenueNT$10.5M
Gross profit-NT$2.8M-27% margin
EBITDA-NT$123.1M-1174% margin
Net income-NT$148.5M-1416.2% margin
Balance sheet & cash
Market capNT$1.5B
Total debtNT$20.2M
Free Cash Flow-NT$138.9M
Profitability & ownership
% insiders32.7%
% institutions12.4%
Last declaration on 24 February 2025
Declarations4 total
- 50,000 sharesShareTPExTWMOPS:6872:114/02/24:龍震宇:0i8c2b1
- 50,000 sharesShareTPExTWMOPS:6872:114/02/24:劉浩澧:01kziws
- 50,000 sharesShareTPExTWMOPS:6872:114/02/24:昌廷光:1nhbwhu
- 50,000 sharesShareTPExTWMOPS:6872:114/02/24:陳正:15s03iy
4 of 4 declarations
About 浩宇生醫
浩宇生醫 is a company listed on the XTAI, specializing in the biotechnology sector. It focuses on developing innovative medical solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
